Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma
Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma
复制标题
高迁移率族蛋白 1 (HMGB1) 表达增加与人鼻咽癌的进展和不良预后相关。
DOI：
10.1002/path.2391
复制
发表时间：
2008-10-01
影响因子：
7.3
通讯作者：
Liu, L.
中科院分区：
文献类型：
--
作者：
Wu, D.;Ding, Y.;Liu, L.
高迁移率族蛋白1(HMGB1)是一种具有核内和细胞外功能的多功能蛋白，参与许多生物学和病理过程，如转录、DNA修复以及对感染和炎症的反应。HMGB1在多种类型的肿瘤中均有表达，但HMGB1在鼻咽癌中的作用尚不清楚。本研究的目的是利用鼻咽癌临床标本分析HMGB1在鼻咽癌进展和临床转归中的作用。免疫组织化学显示HMGB1在166例鼻咽癌中高表达89例(53.6%)。HMGB1过表达与T分期(P=0.003)、N分期(P=0.003)、远处转移(P=0.046)和临床分期(P<；0.001)显著相关。HMGB1表达水平较高的患者总体生存和无病生存较差，而HMGB1表达水平较低的患者生存较好。多因素分析显示，HMGB1表达是患者生存的独立预后指标。用小干扰RNA阻断内源性HMGB1抑制鼻咽癌细胞侵袭能力。这些数据支持HMGB1过度表达在鼻咽癌的进展中起作用的观点，从而导致其不良的临床结果。版权所有(C)2008年大不列颠和爱尔兰病理学会。作者：John Wiley&Sons，Ltd.
High mobility group box 1 (HMGB1) is a versatile protein with intranuclear and extracellular functions that is involved in numerous biological and pathological processes, such as transcription, DNA repair., and response to infection and inflammation. The expression of HMGB1 has been described in many types of cancers, but the role of HMGB1 in nasopharyngeal carcinoma (NPC) is unknown. The aim of this study was to analyse the roles of HMGB1 in NPC progression and clinical outcome using NPC clinical samples. In an immunohistochemical study, HMGB1 had high expression in 89 of 166 cases of NPC (53.6%). HMGB1 overexpression was significantly associated with T classification (p = 0.01), N classification (p = 0.003), distant metastasis (P = 0.046), and clinical stage (p < 0.001). Patients with higher levels of HMGB1 expression had poorer overall survival and disease-free survival, whereas patients with lower levels of HMGB1 expression had better survival. Multivariate analysis showed that HMGB1 expression was an independent prognostic indicator for patient survival. Disruption of endogenous HMGB1 using small interfering RNAs suppressed NPC cell invasive ability. These data support the notion that HMGB1 overexpression has a role in the progression of NPC and hence its poor clinical outcome. Copyright (C) 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.